-
公开(公告)号：EP4056685A1
公开(公告)日：2022-09-14
申请号：EP19951810.1
申请日：2019-11-18
发明人： LIU, Qingsong , LIU, Feiyang , MEI, Husheng , WANG, Wenchao , ZHAO, Ming , JIANG, Zongru , REN, Tao , WANG, Li
摘要： Provided is a culture medium containing amphiregulin for culturing primary breast epithelial cells and a culture method involving using the medium. In the culturing method, primary cells are cultured on a culture vessel coated with an extracellular matrix gel by using the culture medium, and the primary cells grow on the culture vessel, which has been coated with the extracellular matrix gel, and proliferate rapidly under the combined action of nutrient factors and an extracellular matrix contained in the primary cell culture medium. The cell model obtained by the primary cell culture medium and the primary cell culture method can be used for the evaluating the efficacy of and screening drugs.
-
公开(公告)号：EP3466952A1
公开(公告)日：2019-04-10
申请号：EP17805907.7
申请日：2017-06-05
发明人： LIU, Qingsong , LIU, Jing , LI, Xixiang , WANG, Aoli , QI, Ziping , WU, Hong , WU, Jiaxin , WANG, Wenchao , HU, Chen , CHEN, Cheng , WANG, Li , WANG, Beilei
IPC分类号： C07D487/04 , A61K31/5377 , A61K31/519 , A61P35/00 , A61P35/02 , A61P17/06 , A61P13/08
摘要： The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).
-
公开(公告)号：EP3438094A1
公开(公告)日：2019-02-06
申请号：EP17773212.0
申请日：2017-03-28
发明人： LIU, Qingsong , LIU, Jing , WANG, Qiang , WANG, Beilei , LIU, Feiyang , QI, Shuang , QI, Ziping , ZOU, Fengming , CHEN, Cheng , WANG, Wenchao , HU, Chen , LIU, Xiaochuan , WANG, Wei , WANG, Aoli , WANG, Li , HU, Zhenquan , REN, Tao
IPC分类号： C07D211/44 , C07D401/04 , C07D413/04 , C07D413/14 , C07D401/14 , C07D409/14 , A61K31/45 , A61K31/4545 , A61K31/454 , A61P35/00 , A61P35/02
摘要： The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
-
公开(公告)号：EP4286514A1
公开(公告)日：2023-12-06
申请号：EP21921968.0
申请日：2021-02-05
发明人： LIU, Qingsong , HE, Yuying , CHEN, Cheng , HUANG, Tao , REN, Tao , WANG, Wenchao , WANG, Li
摘要： Disclosed are a culture medium and a culture method for in vitro expansion of primary cells of intestinal cancer. The culture medium comprises an initial culture medium, a Rho protease inhibitor, an antibiotic, gastrin, A8301, a non-essential amino acid, cholera toxin, an insulin-like growth factor-1, nicotinamide, insulin, fetal bovine serum, and an additive selected from at least one of a B27 additive and an N2 additive. By using the culture medium, effective and rapid expansion of the primary cells of intestinal cancer can be achieved. The expanded cells maintain the pathological characteristics of patients, and the culture success rate and the cell expansion rate of the primary cells of intestinal cancer are improved, which provide a research foundation for personalized treatment of the patients.
-
5.发明公开
公开(公告)号：EP4137565A1
公开(公告)日：2023-02-22
申请号：EP20930874.1
申请日：2020-04-23
发明人： LIU, Qingsong , HU, Jie , WANG, Wenchao , CHEN, Cheng , REN, Tao , WANG, Li
摘要： Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primay cell culture medium. In the culture method, the primary cell culture medium is used to culture primay cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.
-
公开(公告)号：EP3392245A1
公开(公告)日：2018-10-24
申请号：EP16874860.6
申请日：2016-12-15
发明人： LIU, Jing , LIU, Qingsong , JIANG, Taoshan , WANG, Aoli , WU, Jiaxin , WU, Hong , QI, Ziping , CHEN, Yongfei , ZOU, Fengming , WANG, Wenchao , ZHAO, Zheng , WANG, Li , WANG, Beilei
IPC分类号： C07D401/12 , C07D239/48 , C07D403/12 , C07D239/47 , C07D409/12 , A61K31/506 , A61K31/5377 , A61K31/551 , A61P35/00 , A61P35/02
CPC分类号： A61K31/506 , A61K31/5377 , A61K31/551 , C07D239/47 , C07D239/48 , C07D401/12 , C07D403/12 , C07D409/12 , Y02P20/55
摘要： The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
-
7.发明公开
公开(公告)号：EP4279578A1
公开(公告)日：2023-11-22
申请号：EP21918128.6
申请日：2021-01-22
发明人： LIU, Qingsong , LIU, Feiyang , LI, Xiaoyu , MEI, Husheng , WANG, Wenchao , REN, Tao , WANG, Li
摘要： The present invention provides a cell culture medium for culturing primary gastrointestinal stromal tumor cells, comprising gastrin, N2, insulin, a receptor tyrosine kinase ligand, and a Rock kinase inhibitor. The present invention further provides a method for culturing gastrointestinal stromal tumor cells by using the cell culture medium, and an application and a method of an expanded cell population, which is obtained by using the method, in efficacy evaluation or screening.
-
8.发明公开
公开(公告)号：EP4105320A1
公开(公告)日：2022-12-21
申请号：EP20918987.7
申请日：2020-02-26
发明人： LIU, Qingsong , HU, Jie , CHEN, Cheng , WANG, Wenchao , WANG, Li
IPC分类号： C12N5/09
摘要： Provided are a culture medium and cultivation method of rapidly expanding primary cells of esophageal squamous carcinoma in vitro, and the use thereof in screening drugs. The culture medium comprises an initial culture medium selected from DMEM/F12, DMEM, F12, or RPMI-1640, a Rho protease inhibitor, an antibiotic, insulin, an N2 additive, insulin-like growth factor 1, a non-essential amino acid, and optionally, hydrocortisone, optionally, glutamine, and optionally, bovine pituitary extract.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.013 秒)
